PFE vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 25, 2026

PFE

56.6
AI Score
VS
PFE Wins

GSK

50.3
AI Score

Investment Advisor Scores

PFE

57score
Recommendation
HOLD

GSK

50score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric PFE GSK Winner
Forward P/E 9.5785 9.7656 PFE
PEG Ratio 12.7753 6.1023 GSK
Revenue Growth 2.6% 5.3% GSK
Earnings Growth -10.1% -69.5% PFE
Tradestie Score 56.6/100 50.3/100 PFE
Profit Margin 6.8% 14.5% GSK
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

PFE 1M: -1.5% · 3M: +15.6% GSK 1M: -6.9% · 3M: -12.1%

Current Technical Phase

PFE

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 54

RSI (14): 53.5 · Price: $28.12

GSK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 34

RSI (14): 34.5 · Price: $47.18

Fundamentals Snapshot

Metric PFE GSK
Market Cap — —
Forward P/E 9.7 9.4
Trailing P/E 37.5 15.4
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 0.7%
Operating Margin 0.3% 0.3%
EPS 0.76 3.12
Dividend Yield 0.06% 0.04%

Frequently Asked Questions

Based on our detailed analysis, PFE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.